EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2018

Primary Completion Date

May 31, 2019

Study Completion Date

August 31, 2021

Conditions
AML, AdultMyelodysplastic Syndromes
Interventions
BIOLOGICAL

NKR-2 CAR-T Cells

"The treatment consists in six consecutive cycles of AZA, administered at days~1 to 7 of a 28-day cycle. Patients will be treated with 8 injections of NKR-2 at day 9 and 23 of AZA cycles 2-3-4 and 5."

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celyad Oncology SA

INDUSTRY

NCT03612739 - EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 | Biotech Hunter | Biotech Hunter